Employees: 130
Size SEERS (458870.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $392M, the 406th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩12,380 on 18 Nov 2026.
Performance Over six months the shares fell 69.7%, against -18.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 174.0% over the last twelve months (peer median +13.9%); the operating margin is 36.6% (peer median 4.2%).
Valuation It trades at 15.2× forward earnings against a peer median of 18.2× (4th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +247%, so the hurdle is -253 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 41.0 points above its cost of capital (5.6% WACC).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩91.1B | ₩48.2B | ₩8.10B | ₩1.89B | ₩1.15B |
| Revenue growth | — | +495% | +330% | +63% | — |
| Gross profit | ₩60.7B | ₩34.2B | ₩2.86B | -₩1.30B | -₩829M |
| EBITDA | ₩35.1B | ₩17.6B | -₩7.56B | -₩8.81B | -₩7.48B |
| Net income | ₩33.3B | ₩16.1B | -₩8.87B | -₩9.92B | -₩7.99B |
| Free cash flow | ₩10.9B | ₩610M | -₩11.5B | -₩8.58B | -₩17.3B |
| Capital expenditure | ₩3.40B | ₩2.13B | ₩1.41B | ₩1.11B | ₩8.91B |
| Total debt | ₩5.11B | ₩3.81B | ₩3.05B | ₩6.29B | ₩1.72B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 458870.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -45.7% | -10.9% | lowest of 21 |
| 6-month return | -69.7% | -18.1% | 2nd lowest of 20 |
| Distance from 52-week high | -80.7% | -44.7% | 2nd lowest of 21 |
| Revenue growth (TTM) | +174.0% | +13.9% | 2nd highest of 21 |
| Operating margin | 36.6% | 4.2% | 2nd highest of 21 |
| Forward P/E | 15.2× | 18.2× | 4th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -6.3% | 5.7% | 5th least demanding of 12 |
| Growth delivered (Del g) | +247.0% | +15.4% | highest of 12 |
| Hurdle (Req g minus delivered) | -253.3 pp | +1.8 pp | least demanding of 12 |
| ROIC minus cost of capital | +41.0 pp | -2.1 pp | 2nd highest of 20 |
| EV / EBITDA | 14.3× | 8.5× | 4th most expensive of 9 |
| Net debt / EBITDA | -0.4× | -2.8× | 3rd most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 15.2× | -6.3% | +247.0% |
| Cerus CERS | United States | $392M | -28% | +14% | -12% | n/a | n/a | n/a |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 8.4× | -17.6% | +15.4% |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | n/a | n/a | n/a |
| 908 Devices MASS | United States | $396M | +36% | +14% | -33% | n/a | 41.7% | +15.9% |
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | n/a | -9.5% | -6.6% |
| Guanhao Biotech 300238.SZ | China | $397M | -26% | -12% | 3% | n/a | n/a | n/a |
| Shanghai Titan Scientific 688133.SS | China | $403M | -26% | +1% | -6% | 8.4× | n/a | n/a |
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 11.3× | -10.3% | +16.9% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 37.2× | n/a | n/a |
| Chison Medical Technologies 688358.SS | China | $406M | -27% | -1% | 19% | 19.8× | 9.6% | +5.6% |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | n/a | 17.1% | +18.1% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | n/a | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 25.3× | -4.2% | -6.0% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 20.3× | 24.9% | +18.8% |
| Jenscare Scientific 9877.HK | Hong Kong | $415M | -32% | +993% | -106% | n/a | n/a | n/a |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $418M | -22% | +46% | 8% | n/a | n/a | n/a |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | n/a | n/a | n/a |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 18.2× | 19.1% | +0.1% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | n/a | -13.1% | +36.8% |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 16.4× | 5.7% | +3.4% |